Newron Pharmaceuticals Starts Preclinicals on Compound with Psychiatric Treatment Potential
ZURICH (Thomson Financial) - Newron Pharmaceuticals Spa said it has started preclinical development of a compound called NW-3509, which could potentially be used to treat psychiatric and neurological diseases, such as acute mania.